Okada N, Harada R, Fujita T, Okada H
Department of Microbiology, Fukuoka University School of Medicine, Japan.
Int Immunol. 1989;1(2):205-8. doi: 10.1093/intimm/1.2.205.
Neuraminidase-treated human erythrocytes become sensitive to haemolysis by heterologous serum via activation of the alternative complement pathway (ACP), while remaining insensitive to homologous serum because of the presence of inhibitors on the cell membrane. We obtained a monoclonal antibody which renders the neuraminidase-treated erythrocytes sensitive to haemolysis by homologous human serum via the ACP. This antibody reacts with a 20 KDa membrane glycoprotein which interferes with the terminal stage of complement action on cell membranes. The 20 KDa protein is anchored to the membrane via phosphatidylinositol.
经神经氨酸酶处理的人红细胞通过替代补体途径（ACP）的激活而对异种血清溶血敏感，而由于细胞膜上存在抑制剂，对同种血清仍不敏感。我们获得了一种单克隆抗体，它使经神经氨酸酶处理的红细胞通过ACP对人同种血清溶血敏感。该抗体与一种20 kDa的膜糖蛋白反应，该蛋白干扰补体在细胞膜上作用的终末阶段。20 kDa蛋白通过磷脂酰肌醇锚定在膜上。
